Literature DB >> 8636784

Extensive-disease small-cell lung cancer: the thrill of victory; the agony of defeat.

J Aisner1.   

Abstract

Entities:  

Mesh：

Year:  1996        PMID： 8636784     DOI： 10.1200/JCO.1996.14.2.658

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  7 in total

1.  Secreted human glycyl-tRNA synthetase implicated in defense against ERK-activated tumorigenesis.

Authors:  Min Chul Park; Taehee Kang; Da Jin; Jung Min Han; Sang Bum Kim; Yun Jung Park; Kiwon Cho; Young Woo Park; Min Guo; Weiwei He; Xiang-Lei Yang; Paul Schimmel; Sunghoon Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-15       Impact factor: 11.205

2.  Topoisomerase I inhibitor SN-38 effectively attenuates growth of human non-small cell lung cancer cell lines in vitro and in vivo.

Authors:  Dharmendra Kumar Maurya; Rie Ayuzawa; Chiyo Doi; Deryl Troyer; Masaaki Tamura
Journal:  J Environ Pathol Toxicol Oncol       Date:  2011       Impact factor: 3.567

3.  Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097).

Authors:  Suresh S Ramalingam; Chandra P Belani; Philip C Mack; Everett E Vokes; Jeffrey Longmate; Ramaswamy Govindan; Marianna Koczywas; S Percy Ivy; David R Gandara
Journal:  J Thorac Oncol       Date:  2010-08       Impact factor: 15.609

4.  Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study.

Authors:  Takashi Yana; Shunichi Negoro; Minoru Takada; Soichiro Yokota; Yoshiki Takada; Takahiko Sugiura; Hidehiko Yamamoto; Toshiyuki Sawa; Masaaki Kawahara; Nobuyuki Katakami; Yutaka Ariyoshi; Masahiro Fukuoka
Journal:  Invest New Drugs       Date:  2006-10-13       Impact factor: 3.651

5.  Metabolic burden measured by (18)f-fluorodeoxyglucose positron emission tomography/computed tomography is a prognostic factor in patients with small cell lung cancer.

Authors:  Mi-Hyun Kim; Ji Seok Lee; Jeong Ha Mok; Kwangha Lee; Ki Uk Kim; Hye-Kyung Park; Seong-Jang Kim; Min Ki Lee
Journal:  Cancer Res Treat       Date:  2014-04-22       Impact factor: 4.679

6.  Noxa determines localization and stability of MCL-1 and consequently ABT-737 sensitivity in small cell lung cancer.

Authors:  W Nakajima; M A Hicks; N Tanaka; G W Krystal; H Harada
Journal:  Cell Death Dis       Date:  2014-02-13       Impact factor: 8.469

7.  Multi-institutional phase II trial of irinotecan, cisplatin, and etoposide for sensitive relapsed small-cell lung cancer.

Authors:  K Goto; I Sekine; Y Nishiwaki; R Kakinuma; K Kubota; T Matsumoto; H Ohmatsu; S Niho; T Kodama; T Shinkai; T Tamura; Y Ohe; H Kunitoh; N Yamamoto; H Nokihara; K Yoshida; T Sugiura; K Matsui; N Saijo
Journal:  Br J Cancer       Date:  2004-08-16       Impact factor: 7.640
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.